Sacubitrol calcium salt CAS No.:1369773-39-6
Sacubitrol calcium saltUsage： Used as pharmaceutical intermediate Sacubitrol calcium saltPackaging and Shipping： 25kg/ drum or as per buyer requirement. Sacubitrol calcium saltStorage: Ventilated...
Category：Pharmaceutical Materials
Introduction
Sacubitrol calcium saltUsage： Used as pharmaceutical intermediate Sacubitrol calcium saltPackaging and Shipping： 25kg/ drum or as per buyer requirement. Sacubitrol calcium saltStorage: Ventilated and dry; separate from alkalis, oxidisers, organic materials and flammable materials
| Name | AHU-377 hemicalcium salt |
| Synonyms | (alphar AHU-377 hemicalcium salt AHU-377 (heMicalciuM salt) LCZ696(valsartan + sacubitril) impurity 1 Ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-[1,1′-biphenyl]-4-pentanoate hemicalcium salt Calciumbis(4-{[(1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl] amino} -4-oxobutanoate) |
| CAS | 1369773-39-6 |
| Molecular Formula | C48H56CaN2O10 |
| Molar Mass | 861.04364 |
| Melting Point | >140°C (dec.) |
| Solubility | DMSO (Slightly, Heated), Methanol (Slightly) |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | -20°C |
| In vitro study | Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril hemicalcium salt, a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril hemicalcium salt, does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy. |
| In vivo study | In humans, Sacubitril (AHU-377)(t max 0.5-1.1 h) are absorbed quickly. Sacubitril hemicalcium salt is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h.In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377). |
,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
